Limits...
Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.

Larrinaga G, Perez I, Sanz B, Beitia M, Errarte P, Fernández A, Blanco L, Etxezarraga MC, Gil J, López JI - PLoS ONE (2015)

Bottom Line: Results showed that: 1) mRNA levels and activity of DPPIV increased in colorectal neoplasms (Kruskal-Wallis test, p<0.01); 2) Both adenomas and CRCs displayed positive cytoplasmic immunostaining with luminal membrane reinforcement; 3) Plasmatic DPPIV activity was lower in CRC patients than in healthy subjects (Mann-U test, p<0.01); 4) Plasmatic DPPIV activity was associated with worse overall and disease-free survivals (log-rank p<0.01, Cox analysis p<0.01). 1) Up-regulation of DPPIV in colorectal tumors suggests a role for this enzyme in the neoplastic transformation of colorectal tissues.This finding opens the possibility for new therapeutic targets in these patients. 2) Plasmatic DPPIV is an independent prognostic factor in survival of CRC patients.The determination of DPPIV activity levels in the plasma may be a safe, minimally invasive and inexpensive way to define the aggressiveness of CRC in daily practice.

View Article: PubMed Central - PubMed

Affiliation: Department of Nursing I, School of Nursing, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain; Department of Physiology, Faculty of Medicine and Dentistry,University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain; BioCruces Health Research Institute, Barakaldo, Bizkaia, Spain.

ABSTRACT

Background: Dipeptidyl-peptidase IV (EC 3.4.14.5) (DPPIV) is a serine peptidase involved in cell differentiation, adhesion, immune modulation and apoptosis, functions that control neoplastic transformation. Previous studies have demonstrated altered expression and activity of tissue and circulating DPPIV in several cancers and proposed its potential usefulness for early diagnosis in colorectal cancer (CRC).

Methods and principal findings: The activity and mRNA and protein expression of DPPIV was prospectively analyzed in adenocarcinomas, adenomas, uninvolved colorectal mucosa and plasma from 116 CRC patients by fluorimetric, quantitative RT-PCR and immunohistochemical methods. Results were correlated with the most important classic pathological data related to aggressiveness and with 5-year survival rates. Results showed that: 1) mRNA levels and activity of DPPIV increased in colorectal neoplasms (Kruskal-Wallis test, p<0.01); 2) Both adenomas and CRCs displayed positive cytoplasmic immunostaining with luminal membrane reinforcement; 3) Plasmatic DPPIV activity was lower in CRC patients than in healthy subjects (Mann-U test, p<0.01); 4) Plasmatic DPPIV activity was associated with worse overall and disease-free survivals (log-rank p<0.01, Cox analysis p<0.01).

Conclusion/significance: 1) Up-regulation of DPPIV in colorectal tumors suggests a role for this enzyme in the neoplastic transformation of colorectal tissues. This finding opens the possibility for new therapeutic targets in these patients. 2) Plasmatic DPPIV is an independent prognostic factor in survival of CRC patients. The determination of DPPIV activity levels in the plasma may be a safe, minimally invasive and inexpensive way to define the aggressiveness of CRC in daily practice.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier curves for DPPIV activity in CRC tissues.Overall survival (A) and disease-free survival curves (B) of CRC patients according to their tumor DPPIV activity pattern. The number of patients at risk in each group at individual time points is also included.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4366149&req=5

pone.0119436.g003: Kaplan-Meier curves for DPPIV activity in CRC tissues.Overall survival (A) and disease-free survival curves (B) of CRC patients according to their tumor DPPIV activity pattern. The number of patients at risk in each group at individual time points is also included.

Mentions: Kaplan-Meier curves and log-rank test showed that five-year OS and DFS of patients with CRC was not correlated with tissue DPPIV activity (log-rank test, p = 0.8 for OS; and p = 0.67 for DFS) (Fig. 3A and 3B, respectively).


Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.

Larrinaga G, Perez I, Sanz B, Beitia M, Errarte P, Fernández A, Blanco L, Etxezarraga MC, Gil J, López JI - PLoS ONE (2015)

Kaplan-Meier curves for DPPIV activity in CRC tissues.Overall survival (A) and disease-free survival curves (B) of CRC patients according to their tumor DPPIV activity pattern. The number of patients at risk in each group at individual time points is also included.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4366149&req=5

pone.0119436.g003: Kaplan-Meier curves for DPPIV activity in CRC tissues.Overall survival (A) and disease-free survival curves (B) of CRC patients according to their tumor DPPIV activity pattern. The number of patients at risk in each group at individual time points is also included.
Mentions: Kaplan-Meier curves and log-rank test showed that five-year OS and DFS of patients with CRC was not correlated with tissue DPPIV activity (log-rank test, p = 0.8 for OS; and p = 0.67 for DFS) (Fig. 3A and 3B, respectively).

Bottom Line: Results showed that: 1) mRNA levels and activity of DPPIV increased in colorectal neoplasms (Kruskal-Wallis test, p<0.01); 2) Both adenomas and CRCs displayed positive cytoplasmic immunostaining with luminal membrane reinforcement; 3) Plasmatic DPPIV activity was lower in CRC patients than in healthy subjects (Mann-U test, p<0.01); 4) Plasmatic DPPIV activity was associated with worse overall and disease-free survivals (log-rank p<0.01, Cox analysis p<0.01). 1) Up-regulation of DPPIV in colorectal tumors suggests a role for this enzyme in the neoplastic transformation of colorectal tissues.This finding opens the possibility for new therapeutic targets in these patients. 2) Plasmatic DPPIV is an independent prognostic factor in survival of CRC patients.The determination of DPPIV activity levels in the plasma may be a safe, minimally invasive and inexpensive way to define the aggressiveness of CRC in daily practice.

View Article: PubMed Central - PubMed

Affiliation: Department of Nursing I, School of Nursing, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain; Department of Physiology, Faculty of Medicine and Dentistry,University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain; BioCruces Health Research Institute, Barakaldo, Bizkaia, Spain.

ABSTRACT

Background: Dipeptidyl-peptidase IV (EC 3.4.14.5) (DPPIV) is a serine peptidase involved in cell differentiation, adhesion, immune modulation and apoptosis, functions that control neoplastic transformation. Previous studies have demonstrated altered expression and activity of tissue and circulating DPPIV in several cancers and proposed its potential usefulness for early diagnosis in colorectal cancer (CRC).

Methods and principal findings: The activity and mRNA and protein expression of DPPIV was prospectively analyzed in adenocarcinomas, adenomas, uninvolved colorectal mucosa and plasma from 116 CRC patients by fluorimetric, quantitative RT-PCR and immunohistochemical methods. Results were correlated with the most important classic pathological data related to aggressiveness and with 5-year survival rates. Results showed that: 1) mRNA levels and activity of DPPIV increased in colorectal neoplasms (Kruskal-Wallis test, p<0.01); 2) Both adenomas and CRCs displayed positive cytoplasmic immunostaining with luminal membrane reinforcement; 3) Plasmatic DPPIV activity was lower in CRC patients than in healthy subjects (Mann-U test, p<0.01); 4) Plasmatic DPPIV activity was associated with worse overall and disease-free survivals (log-rank p<0.01, Cox analysis p<0.01).

Conclusion/significance: 1) Up-regulation of DPPIV in colorectal tumors suggests a role for this enzyme in the neoplastic transformation of colorectal tissues. This finding opens the possibility for new therapeutic targets in these patients. 2) Plasmatic DPPIV is an independent prognostic factor in survival of CRC patients. The determination of DPPIV activity levels in the plasma may be a safe, minimally invasive and inexpensive way to define the aggressiveness of CRC in daily practice.

No MeSH data available.


Related in: MedlinePlus